… had tested positive for recombinant erythropoietin (rEPO) after officials conducted a … , 35, tested positive for recombinant erythropoietin (rEPO) as the result of … suspension after he failed a drug test following his Bellator 300 …

… a year after failing a drug test. The featherweight champion provided … came back positive for recombinant erythropoietin on the same day he … teammate was using performance-enhancing drugs. Conor McGregor reignites interest in …

"Khaybulaev forfeits the distinction of 2025 PFL Featherweight Tournament Champion, the championship belt, and all associated bonus awards," the PFL said. "The PFL maintains a zero-tolerance policy toward the use of performance-enhancing …

… one year after failing a drug test. The 2025 PFL featherweight … that tested positive for recombinant erythropoietin on August 1, the day … commented on Khaybulaev’s failed drug test and subsequent ban. ‘However …

… Agency after submitting a positive drug test in competition for … 35, tested positive for recombinant erythropoietin (rEPO) as the result of … help increase stamina.The positive drug test for Khaybulaev came … overturned due to the positive drug test. That’s a …

… stress. Novel interventions, such as erythropoietin administration, stem cell therapy, … genomic era integration epitomizes precision medicine’s promise in neonatal … bridging diagnostic precision with personalized treatment regimens. This integrated approach …

… ; Drug Administration (FDA) granted roxadustat an Orphan Drug Designation for the treatment of … from the Phase 3 MATTHERHORN trial, which, along with its … stimulates erythropoiesis by increasing endogenous erythropoietin production, enhancing iron absorption …

… Drug Administration (FDA) has granted roxadustat Orphan Drug Designation for the treatment … Roxadustat, an oral medication, is the first … endogenous production of erythropoietin, improved iron absorption … potential future clinical trials, and other matters …

… Medicine, a clinical-stage generative artificial intelligence (AI)-driven drug … Biotechnology, a listed discovery-based and market-focused pharmaceutical … anemia, due to less Erythropoietin (EPO)—a hormone … HIF‑α pathway for the treatment of CKD-related anemia …

… treatment of CKD-related anaemia in Greater China. Insilico Medicine … collaboration with TaiGen Biotechnology and its wholly … due to reduced levels of erythropoietin (EPO) – a … AI-driven drug discovery with established pharmaceutical development expertise. …